[ad_1]
(Photo from Anatolia)
MOSCOW The results of the interim trial show that the Russian vaccine Sputnik V against the 2019 coronavirus disease (Covid-19) has an efficiency of more than 95 percent, the developer said Tuesday.
The current efficiency was reached on the 42nd day, when the recipients already formed a stable immune response, according to a Twitter statement from the Russian Direct Investment Fund.
Russia is currently conducting Phase 3 trials of the Sputnik V vaccine, with the participation of 40,000 people, the statement added.
“As of November 24, no unexpected adverse complications were detected during the Sputnik V study. Some of the vaccinated patients experienced short-term complaints, such as injection site pain, flu-like syndrome, including fever, weakness , fatigue and headache, “it said.
The data obtained during the trials will be published by the research team of the Gamaleya Epidemiology and Microbiology Research Institute, which developed the vaccine, in one of the main international medical issues.
At the end of the third phase of clinical trials, the institute will provide access to the full trial report, he said.
Russia became the first country in the world to register a coronavirus vaccine for use, called Gam-Covid-Vac (Vacuna Gamaleya Covid) by the developers and under the trade name Sputnik V, with V referring to the vaccine.
The vaccine is designed to be given as two injections to prolong immunity, and at the current stage, it is licensed for people ages 18 to 60 and can be combined with other antigens, including against the flu. (Anatolia)
[ad_2]
